<DOC>
	<DOCNO>NCT02616003</DOCNO>
	<brief_summary>The frequency patient BMI 70 kg/m2 need immediate weight loss surgery risen continuously . For patient prior-to-surgery conditioning therapy mandatory gain technical physical operability . The exclusively well-established preliminary therapy far intragastric balloon , take 7 month treatment time . Due life-threatening condition giant obese patient , admit hospital , investigator force develop prompt act condition therapy bring individual short run improve `` fit-for-surgery '' state . In impasse investigator combine Liraglutide well-known weight-loss effect leucine-based amino acid infusion generally use patient liver insufficiency , expectance additional weight loss liver reduction effect .</brief_summary>
	<brief_title>Preoperative Condition Giant Obese Patients</brief_title>
	<detailed_description>The investigator use commercial available amino acid infusion ( Aminosteril hepa 8 % , Fresenius Karbi ) , use clinical application liver conditioning . It mainly base branched-chained amino acid leucine ( 13.09 g per 1000 ml ) . The investigator combine daily subcutaneous injection Liraglutide . Liraglutide GLP-1 analogue , achieve meanwhile FDA approval weight loss treatment . Initial Liraglutide dosage 1.2 mg three day , boost 1.8 mg consecutively . Participants receive energy reduce nutrition 800 kcal/d .</detailed_description>
	<mesh_term>Obesity , Morbid</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>BMI 65 kg/m2 renal insufficiency III</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Morbid Obesity</keyword>
	<keyword>Giant Obese</keyword>
	<keyword>Preoperative Procedure</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>Leucine</keyword>
</DOC>